vs
爱德华生命科学（EW）与RENAISSANCERE HOLDINGS LTD（RNR）财务数据对比。点击上方公司名可切换其他公司
RENAISSANCERE HOLDINGS LTD的季度营收约是爱德华生命科学的1.3倍（$2.2B vs $1.6B），RENAISSANCERE HOLDINGS LTD净利率更高（23.5% vs 23.1%，领先0.4%），爱德华生命科学同比增速更快（16.7% vs -36.8%），过去两年爱德华生命科学的营收复合增速更高（9.7% vs -11.9%）
爱德华生命科学是总部位于美国加利福尼亚州尔湾的医疗科技企业，专注于人工心脏瓣膜及血流动力学监测领域，其研发的Sapien经导管主动脉心脏瓣膜采用牛组织材质，搭配球囊扩张式钴铬合金支架，可通过导管完成植入。
RenaissanceRe Holdings Ltd是总部位于百慕大的保险及相关商业服务提供商，核心业务覆盖再保险、常规保险两大板块，同时运营风险相关创新投资业务，为全球客户提供专业的风险对冲与保险解决方案。
EW vs RNR — 直观对比
营收规模更大
RNR
是对方的1.3倍
$1.6B
营收增速更快
EW
高出53.5%
-36.8%
净利率更高
RNR
高出0.4%
23.1%
两年增速更快
EW
近两年复合增速
-11.9%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.6B | $2.2B |
| 净利润 | $380.7M | $515.8M |
| 毛利率 | 78.0% | — |
| 营业利润率 | 1.8% | — |
| 净利率 | 23.1% | 23.5% |
| 营收同比 | 16.7% | -36.8% |
| 净利润同比 | 6.8% | 72.6% |
| 每股收益（稀释后） | $0.66 | $6.57 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EWRNR
| Q1 26 | $1.6B | $2.2B | ||
| Q4 25 | $1.6B | $3.0B | ||
| Q3 25 | $1.6B | $3.2B | ||
| Q2 25 | $1.5B | $3.2B | ||
| Q1 25 | $1.4B | $3.5B | ||
| Q4 24 | $1.4B | $2.3B | ||
| Q3 24 | $1.4B | $4.0B | ||
| Q2 24 | $1.4B | $2.8B |
净利润EWRNR
| Q1 26 | $380.7M | $515.8M | ||
| Q4 25 | $91.2M | $760.5M | ||
| Q3 25 | $291.1M | $916.5M | ||
| Q2 25 | $333.2M | $835.4M | ||
| Q1 25 | $358.0M | $170.0M | ||
| Q4 24 | $385.6M | $-189.7M | ||
| Q3 24 | $3.1B | $1.2B | ||
| Q2 24 | $366.3M | $503.9M |
毛利率EWRNR
| Q1 26 | 78.0% | — | ||
| Q4 25 | 78.1% | — | ||
| Q3 25 | 77.8% | — | ||
| Q2 25 | 77.5% | — | ||
| Q1 25 | 78.7% | — | ||
| Q4 24 | 78.9% | — | ||
| Q3 24 | 80.6% | — | ||
| Q2 24 | 79.9% | — |
营业利润率EWRNR
| Q1 26 | 1.8% | — | ||
| Q4 25 | 9.6% | 42.5% | ||
| Q3 25 | 19.8% | 46.3% | ||
| Q2 25 | 26.8% | 41.8% | ||
| Q1 25 | 27.9% | -2.0% | ||
| Q4 24 | 22.6% | -3.6% | ||
| Q3 24 | 25.9% | 43.7% | ||
| Q2 24 | 26.8% | 25.0% |
净利率EWRNR
| Q1 26 | 23.1% | 23.5% | ||
| Q4 25 | 5.8% | 25.6% | ||
| Q3 25 | 18.7% | 28.7% | ||
| Q2 25 | 21.7% | 26.1% | ||
| Q1 25 | 25.3% | 4.9% | ||
| Q4 24 | 27.8% | -8.3% | ||
| Q3 24 | 226.7% | 29.8% | ||
| Q2 24 | 26.7% | 17.8% |
每股收益（稀释后）EWRNR
| Q1 26 | $0.66 | $6.57 | ||
| Q4 25 | $0.16 | $16.16 | ||
| Q3 25 | $0.50 | $19.40 | ||
| Q2 25 | $0.56 | $17.20 | ||
| Q1 25 | $0.61 | $3.27 | ||
| Q4 24 | $0.65 | $-3.76 | ||
| Q3 24 | $5.13 | $22.62 | ||
| Q2 24 | $0.61 | $9.41 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $1.6B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | — | $4.3B |
| 总资产 | — | $53.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EWRNR
| Q1 26 | — | $1.6B | ||
| Q4 25 | $4.2B | $1.7B | ||
| Q3 25 | $3.8B | $1.7B | ||
| Q2 25 | $4.1B | $1.4B | ||
| Q1 25 | $3.9B | $1.6B | ||
| Q4 24 | $4.0B | $1.7B | ||
| Q3 24 | $4.4B | $1.6B | ||
| Q2 24 | $2.0B | $1.6B |
总债务EWRNR
| Q1 26 | — | — | ||
| Q4 25 | — | $2.3B | ||
| Q3 25 | — | $2.2B | ||
| Q2 25 | — | $2.3B | ||
| Q1 25 | — | $2.8B | ||
| Q4 24 | — | $1.9B | ||
| Q3 24 | — | $1.9B | ||
| Q2 24 | — | $2.0B |
股东权益EWRNR
| Q1 26 | — | $4.3B | ||
| Q4 25 | $10.3B | $11.6B | ||
| Q3 25 | $10.2B | $11.5B | ||
| Q2 25 | $10.5B | $10.8B | ||
| Q1 25 | $10.1B | $10.3B | ||
| Q4 24 | $10.0B | $10.6B | ||
| Q3 24 | $9.5B | $11.2B | ||
| Q2 24 | $7.4B | $10.2B |
总资产EWRNR
| Q1 26 | — | $53.7B | ||
| Q4 25 | $13.7B | $53.8B | ||
| Q3 25 | $13.3B | $54.5B | ||
| Q2 25 | $13.5B | $54.7B | ||
| Q1 25 | $13.0B | $53.6B | ||
| Q4 24 | $13.1B | $50.7B | ||
| Q3 24 | $13.0B | $52.8B | ||
| Q2 24 | $10.1B | $51.6B |
负债/权益比EWRNR
| Q1 26 | — | — | ||
| Q4 25 | — | 0.20× | ||
| Q3 25 | — | 0.19× | ||
| Q2 25 | — | 0.21× | ||
| Q1 25 | — | 0.27× | ||
| Q4 24 | — | 0.18× | ||
| Q3 24 | — | 0.17× | ||
| Q2 24 | — | 0.19× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
